Chengdu, China – January 12, 2026 – Full-Life Technologies (“Full-Life”), a fully-integrated global radiopharmaceutical company today congratulates its partner SK Biopharmaceuticals Co., Ltd. (“SK Biopharmaceuticals”) on receiving the U.S. Food and Drug Administration (“FDA”) approval of the Phase 1 Investigational New Drug (“IND”) for its radiopharmaceutical therapeutic candidate SKL35501 and imaging agent SKL35502. The therapeutic candidate SKL35501 was in-licensed by SK Biopharmaceuticals from Full-Life in July 2024. The imaging agent SKL35502 utilizes the same NTSR1 target as SKL35501.

Chengdu, China, and Gembloux, Belgium – September 30, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, today announced the completion of US$77 million financing, comprised of close to US$50 million Series C equity and US$27 million debt financing. This financing will advance development of the Company's radiopharmaceutical pipeline worldwide and manufacturing capabilities in Belgium.

Shanghai, China, and Gembloux, Belgium – September 25, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced its participation in the 38th Annual Congress of the European Association of Nuclear Medicine ("EANM"), taking place in Barcelona, Spain from October 4 to 8, 2025. The Company has been selected to deliver two Top-Rated Oral Presentations ("TROP") based on accepted abstracts. In addition, the Company will host an exhibition booth, and an e-poster will be displayed at the congress.

Heidelberg, Germany, and Shanghai, China – May 27, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced that the Company will participate ASCO (“American Society of Clinical Oncology”) 2025 annual meeting and deliver a poster presentation on June 2nd, 2025, 9:00 AM CT.

Heidelberg, Germany and Shanghai, China – May 8, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced the appointment of Debora Barton, MD, as Chief Medical Officer.